ValbiotisXPAR:ALVAL -7.22%55 Days Payable is 152.32 as of Dec. 2025, which is 98% below its 10-year median of 7,362.73. GuruFocus rates XPAR:ALVAL with a GF Score™ of 55/100 and a GF Value™ of €1.49 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,883 Consumer Packaged Goods companies, Valbiotis ranks better than 93.41% on this metric.
Valbiotis's average Accounts Payable for the
six
months ended in Dec. 2025 was €0.98 Mil. Valbiotis's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €1.17 Mil.
Hence, Valbiotis's Days Payable for the
six
months ended in Dec. 2025 was 152.32.
The historical rank and industry rank for Valbiotis's Days Payable or its related term are showing as below:
XPAR:ALVAL'
s Days Payable Range Over the Past 10 Years
Min: 183.48 Med: 7362.73 Max: 93531.25
Current: 188.29
During the past 11 years, Valbiotis's highest Days Payable was 93531.25. The lowest was 183.48. And the median was 7362.73.
XPAR:ALVAL's Days Payable is ranked better than 93.41% of 1883
companies
in the Consumer Packaged Goods industry
Industry Median: 44.15
vs XPAR:ALVAL: 188.29
Valbiotis's Days Payable
increased
from Dec. 2024 (139.62) to Dec. 2025 (152.32).
It may suggest that Valbiotisdelayed paying its suppliers.
Valbiotis Days Payable Related Terms
Valbiotis Days Payable Historical Data
* Premium members only.
The historical data trend for Valbiotis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Valbiotis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valbiotis Days Payable vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's Days Payable distribution charts can be found below:
* The bar in red indicates where Valbiotis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Valbiotis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valbiotis (XPAR:ALVAL) has a Days Payable of 152.32 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Valbiotis and its competitors. This is 98% below median its historical median of 7,362.73. Over the past decade, Valbiotis' Days Payable has ranged from 183.48 to 93,531.25. According to the industry distribution chart, Valbiotis ranks #124 out of 1883 companies in the Consumer Packaged Goods industry, placing it in the top 6.6%.
Is Valbiotis' Days Payable too high?
Valbiotis' current Days Payable of 152.32 is 98% below median its 10-year median of 7,362.73. Over the past 10 years, this metric has ranged from a low of 183.48 to a high of 93,531.25. The Consumer Packaged Goods industry median Days Payable is 44.15. Valbiotis' value of 152.32 is 245% above this industry median. Based on the distribution chart, Valbiotis ranks #124 out of 1883 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Valbiotis has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' Days Payable compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Valbiotis ranks #124 out of 1883 companies for Days Payable. This places Valbiotis in the top 7% of its industry — outperforming the majority of peers. The industry median Days Payable is 44.15. Valbiotis' value of 152.32 is 245% above this benchmark. Historically, Valbiotis' own Days Payable has ranged from 183.48 to 93,531.25 over the past decade. While the company's 10-year median is 7,362.73 vs. the industry median of 44.15, Valbiotis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Consumer Packaged Goods company?
The median Days Payable among Consumer Packaged Goods companies is 44.15, based on 1,883 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valbiotis's current Days Payable of 152.32 is 245% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Valbiotis and its competitors. For the Consumer Packaged Goods industry, the median Days Payable is 44.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valbiotis's current Days Payable is 152.32, which is 98% below median its own 10-year median of 7,362.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.49, compared to a current price of €0.75 — trading 50% below its estimated fair value. The current Days Payable is 152.32, which is 98% below median its 10-year median of 7,362.73 and 245% above the Consumer Packaged Goods industry median of 44.15. Valbiotis' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current Days Payable is 152.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?
Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued.
The current stock price of €0.75 is trading 50% below its estimated GF Value™ of €1.49.
GuruFocus considers Valbiotis to be Possible Value Trap.
Key valuation signals for XPAR:ALVAL:
Days Payable: 152.32 (98% below median its 10-year median of 7,362.73)
GF Value™: €1.49 vs. price of €0.75 (50% below fair value)
Industry Position: 245% above the Consumer Packaged Goods median (#124 of 1883)
No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
55GF Score
Get the complete analysis for XPAR:ALVAL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVAL has been successfully added to your 
